325 related articles for article (PubMed ID: 30610952)
21. Nasal benzodiazepines for management of acute childhood seizures?
Wallace SJ
Lancet; 1997 Jan; 349(9047):222. PubMed ID: 9014904
[No Abstract] [Full Text] [Related]
22. Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats.
Bshara H; Osman R; Mansour S; El-Shamy Ael-H
Carbohydr Polym; 2014 Jan; 99():297-305. PubMed ID: 24274510
[TBL] [Abstract][Full Text] [Related]
23. Brain targeting of chitosan-based diazepam mucoadhesive microemulsions via nasal route: formulation optimization, characterization, pharmacokinetic and pharmacodynamic evaluation.
Ramreddy S; Janapareddi K
Drug Dev Ind Pharm; 2019 Jan; 45(1):147-158. PubMed ID: 30230386
[TBL] [Abstract][Full Text] [Related]
24. Drug Delivery and Targeting to the Brain Through Nasal Route: Mechanisms, Applications and Challenges.
Kashyap K; Shukla R
Curr Drug Deliv; 2019; 16(10):887-901. PubMed ID: 31660815
[TBL] [Abstract][Full Text] [Related]
25. Nanoneurotherapeutics approach intended for direct nose to brain delivery.
Md S; Mustafa G; Baboota S; Ali J
Drug Dev Ind Pharm; 2015; 41(12):1922-34. PubMed ID: 26057769
[TBL] [Abstract][Full Text] [Related]
26. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
27. Nose-to-brain delivery of levetiracetam after intranasal administration to mice.
Gonçalves J; Bicker J; Gouveia F; Liberal J; Oliveira RC; Alves G; Falcão A; Fortuna A
Int J Pharm; 2019 Jun; 564():329-339. PubMed ID: 31015006
[TBL] [Abstract][Full Text] [Related]
28. Carbamazepine-loaded solid lipid nanoparticles and nanostructured lipid carriers: Physicochemical characterization and in vitro/in vivo evaluation.
Scioli Montoto S; Sbaraglini ML; Talevi A; Couyoupetrou M; Di Ianni M; Pesce GO; Alvarez VA; Bruno-Blanch LE; Castro GR; Ruiz ME; Islan GA
Colloids Surf B Biointerfaces; 2018 Jul; 167():73-81. PubMed ID: 29627680
[TBL] [Abstract][Full Text] [Related]
29. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration.
Gartziandia O; Herran E; Pedraz JL; Carro E; Igartua M; Hernandez RM
Colloids Surf B Biointerfaces; 2015 Oct; 134():304-13. PubMed ID: 26209963
[TBL] [Abstract][Full Text] [Related]
30. Quantitative analysis of drug delivery to the brain via nasal route.
Kozlovskaya L; Abou-Kaoud M; Stepensky D
J Control Release; 2014 Sep; 189():133-40. PubMed ID: 24997277
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticle transport across in vitro olfactory cell monolayers.
Gartziandia O; Egusquiaguirre SP; Bianco J; Pedraz JL; Igartua M; Hernandez RM; Préat V; Beloqui A
Int J Pharm; 2016 Feb; 499(1-2):81-89. PubMed ID: 26721725
[TBL] [Abstract][Full Text] [Related]
32. Nanosystems, Drug Molecule Functionalization and Intranasal Delivery: An Update on the Most Promising Strategies for Increasing the Therapeutic Efficacy of Antidepressant and Anxiolytic Drugs.
Antunes JL; Amado J; Veiga F; Paiva-Santos AC; Pires PC
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986859
[TBL] [Abstract][Full Text] [Related]
33. Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design.
Jojo GM; Kuppusamy G; De A; Karri VVSNR
Drug Dev Ind Pharm; 2019 Jul; 45(7):1061-1072. PubMed ID: 30922126
[TBL] [Abstract][Full Text] [Related]
34. Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery.
Salatin S; Barar J; Barzegar-Jalali M; Adibkia K; Milani MA; Jelvehgari M
Arch Pharm Res; 2016 Sep; 39(9):1181-92. PubMed ID: 27352214
[TBL] [Abstract][Full Text] [Related]
35. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
[TBL] [Abstract][Full Text] [Related]
36. Intranasal nanoparticulate delivery systems for neurodegenerative disorders: a review.
Babu SR; Shekara HH; Sahoo AK; Harsha Vardhan PV; Thiruppathi N; Venkatesh MP
Ther Deliv; 2023 Sep; 14(9):571-594. PubMed ID: 37691577
[TBL] [Abstract][Full Text] [Related]
37. Intranasal delivery of topiramate nanoemulsion: Pharmacodynamic, pharmacokinetic and brain uptake studies.
Patel RJ; Parikh RH
Int J Pharm; 2020 Jul; 585():119486. PubMed ID: 32502686
[TBL] [Abstract][Full Text] [Related]
38. Nanosystems for Brain Targeting of Antipsychotic Drugs: An Update on the Most Promising Nanocarriers for Increased Bioavailability and Therapeutic Efficacy.
Ferreira MD; Duarte J; Veiga F; Paiva-Santos AC; Pires PC
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840000
[TBL] [Abstract][Full Text] [Related]
39. Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder.
Bari NK; Fazil M; Hassan MQ; Haider MR; Gaba B; Narang JK; Baboota S; Ali J
Int J Biol Macromol; 2015 Nov; 81():49-59. PubMed ID: 26210037
[TBL] [Abstract][Full Text] [Related]
40. Nanotechnological advances in the treatment of epilepsy: a comprehensive review.
Rai G; Sharma S; Bhasin J; Aggarwal K; Ahuja A; Dang S
Nanotechnology; 2024 Jan; 35(15):. PubMed ID: 38194705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
